EP0551394A1 - Trichoderma reesei, die deletierte und/oder angereichertef zellulase und andere enzymgene enthält, und zellulasezusammensetzungen, die sich daraus ableiten - Google Patents

Trichoderma reesei, die deletierte und/oder angereichertef zellulase und andere enzymgene enthält, und zellulasezusammensetzungen, die sich daraus ableiten

Info

Publication number
EP0551394A1
EP0551394A1 EP19910918551 EP91918551A EP0551394A1 EP 0551394 A1 EP0551394 A1 EP 0551394A1 EP 19910918551 EP19910918551 EP 19910918551 EP 91918551 A EP91918551 A EP 91918551A EP 0551394 A1 EP0551394 A1 EP 0551394A1
Authority
EP
European Patent Office
Prior art keywords
reesei
dna
gene
cellulase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910918551
Other languages
English (en)
French (fr)
Inventor
Michael Ward
Sharon P. Shoemaker
Geoffrey L. Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24376762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0551394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genencor International Inc filed Critical Genencor International Inc
Publication of EP0551394A1 publication Critical patent/EP0551394A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
    • D06M16/003Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic with enzymes or microorganisms
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38645Preparations containing enzymes, e.g. protease or amylase containing cellulase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M2200/00Functionality of the treatment composition and/or properties imparted to the textile material
    • D06M2200/50Modified hand or grip properties; Softening compositions

Definitions

  • the present invention relates to a process for transforming the filamentous fungus Trichoderma reesei: to transformation of Trichoderma reesei with homologous DNA including a selectable marker for transforming Trichoderma reesei; to deletion of Trichoderma reesei genes by transformation with linear DNA fragments of substantially homologous DNA; to insertion of Trichoderma reesei genes by transformation with linear DNA fragments of substantially homologous DNA; to useful fungal transformants produced from Trichoderma reesei by genetic engineering techniques; and to cellulase compositions produced by such transformants.
  • Cellulases are enzyme compositions which hydrolyze cellulose ( ⁇ -1 ,4-D-glucan linkages) and/or its derivatives (eg., phosphoric acid swollen cellulose) and give as primary products glucose, cellobiose, cellooligosaccharide, and the like.
  • a cellulase system produced by a given microorganism is comprised of several different enzyme classifications including those identified as exo-cellobiohydrolases (EC 3.2.1 .91 ) (“CBH”), endoglucanases (EC 3.2.1 .4) (“EG”), and ⁇ -glucosidases (EC 3.2.1.21 ) (“BG”) (Schulein, M., 1988).
  • T. reesei Trichoderma reesei
  • CBHI and CBHII Trichoderma reesei
  • EGI, EGII and EGIII components Trichoderma reesei
  • T. reesei has also been referred to in the literature as Trichoderma longibrachiatum Rifai (Cannon, P.F., 1986, Microbiol. Sci. 3 pp. 285-287).
  • EGII has been previously referred to by the nomenclature “EGIII” by some authors but current nomenclature uses the term “EGII”.
  • EGII protein is substantially different from the EGIII protein stated herein in its molecular weight, pi, and pH optimum.
  • the complete cellulase system comprising CBH, EG, and BG components is required to efficiently convert crystalline cellulose to glucose. Isolated components are far less effective, if useful at all, in hydrolyzing crystalline cellulose. Moreover, a synergistic relationship is observed between the cellulase components CBH, EG and BG on crystalline cellulose. That is to say the effectiveness of the com- plete/whole system to solubilize cellulose is significantly greater than the sum of the contributions from the isolated components. It also has been shown that CBHI- and CBHII-type components derived from either T. reesei or F ⁇ funiculosum act synergistically in solubilizing cotton fibers (Wood, 1985). Moreover, it has been disclosed that CBHI (derived from T. reesei). by itself, has the highest binding affinity but the lowest specific activity of all forms of cellulase components component which may account for the synergy of the combined components.
  • the endoglucanases act on internal linkages (with higher rates of reaction on cellulose regions of low crystallinity) and give as principle soluble products, cellobiose, glucose and cellooligosaccharides.
  • the exo- cellobiohydrolases act from the non-reducing end of the cellulose polymer chains to give cellobiose as the principle product, ⁇ - glucosidases do not act on the polymer but act on soluble cellooligosaccharides from the non-reducing end to give glucose as the sole product.
  • Cellulase is also known in the art to be useful in detergent compositions either for the purpose of enhancing the cleaning ability of the composition or as a softening agent. When so used, the cellulase will degrade a portion of the cellulosic material, e.g., cotton fabric, in the wash which in one manner or another facilitates the cleaning and/or the softening of the cotton fabric. While the exact cleaning and softening mechanisms of cotton fabrics by cellulase are not fully understood, the cleaning and softening of cotton fabrics by cellulase has been attributed to different components found in the cellulase. For example, U.S. Patent Application Serial No. 07/422,814 (abandoned in favor of continuation application U.S. Patent Application Serial No.
  • Xylanase is known in the art to be useful in a number of commercial processes.
  • the xylanase enzymes are generally used to hydrolyze and/or modify xylan containing polymers which are associated with hemicellulose and other plant polysaccharides.
  • Xylanase enzymes have been found to be useful in a variety of applications including but not limited to the bleaching of wood pulps and the modification of cereals and grains for use in baking and the production of animal feeds. Construction of microbial strains, via genetic techniques, to overexpress the xylanase proteins free of cellulolytic enzymes would greatly enhance the commercial utility of xylanase.
  • Transformation is a known process for transferring genetic material into a host microorganism. This process has been well established in procaryotic systems, but in higher organisms such as eukaryotes, transformation in many instances is still in experimental stages. Transformation in fungi has been limited in part because of the low permeability of the cell wall, which in many instances tends to restrict the uptake of DNA into the host strain.
  • a transformation system in the yeast Saccharomvces cerevisiae recently has been developed by digesting the outer wall of the yeast cells with various enzymes, thus aiding in DNA uptake in the host. Cloned DNA sequences were introduced into the host and homologous recombination occurred.
  • the plasmid integrated into the genome by recombination between a DNA segment in the genome and a similar DNA segment present on the plasmid.
  • some plasmids are capable of autonomous replication and exist free from the host cell genome in yeast.
  • T. reesei In the past, transformation methods for T. reesei have used foreign DNA in the vector system which contains a selectable marker capable of being incorporated into the host strain. Circular vectors incorporating bacterial plasmid DNA have been used and the selectable marker gene has been derived from another species. For instance, in European Patent Application No. 0,244,234, T. reesei was transformed using selectable markers of ar ⁇ B. trpC or amds from the species Asper ⁇ illus nidulans. Also disclosed is the use of pyr4 from the species Neurospora crassa. All of the selectable markers are genes which are heterologous to the host strain and therefore foreign DNA is introduced into the derivative strain.
  • transformation of fungi to produce various proteins is often unpredictable. Different methods often are used to transform different strains and the DNA is not always integrated at the designated position in the genome.
  • the selection of a host microorganism is vital in the transformation process.
  • the microorganism must be able to be transformed by integration of recombinant DNA at the homologous region of the genome in at least some fraction of the transformants and seldom with additional integration at secondary sites and be able to produce the desired protein product in quantities that are commercially marketable.
  • T. reesei is one such strain.
  • Trichoderma transformants obtained using a pyr gene as a selectable marker show a high degree of instability in contrast to equivalent transformants of Asper ⁇ illus niger and Neurospora crassa (Gruber et al., 1990, Smith et al., 1991 ).
  • T. reesei is the host microorganism of choice, it was unpredictable whether homologous recombination could be achieved in this host fungus.
  • T ⁇ reesei can be transformed with linear homologous DNA fragments, excised from plasmids, which can integrate at homologous sites in the genome.
  • the derivative strains produced by this transformation method may lack particular genes because of homologous integration of the linear DNA fragment into a copy of this gene locus within the genome.
  • the transformants produced by the transformation do not contain any foreign DNA and thus secrete proteins, such as cellulase enzymes, that are free of any foreign protein.
  • the derivative strains produced by this transformation method may overexpress particular genes because of the homologous integration of a linear DNA fragment containing a functional gene into the gene locus of another gene within the genome.
  • the present invention is directed to a process for transforming T. reesei. which process comprises the steps of:
  • the present invention is directed to novel and useful transformants of T. reesei which can be used to synthesize cellulase compositions, especially cellulase compositions deleted or enriched in one or more components and which produce only homologous proteins.
  • the present invention is directed to a fungal cellulase composition derived from the transformed T. reesei strains which is lacking cellulase proteins selected from the group consisting of one or more CBHI-, CBHII-, EGI-, EGII- and EGIII components which composition is free of heterologous proteins.
  • the present invention is directed to a fungal xylanase composition derived from the transformed T.reesei strains which is deleted or enriched in one or more xylanase proteins which composition is free of heterologous proteins.
  • the present invention is directed towards the preparation of a particular plasmid, part of which plasmid is homologous to the T.reesei strain and contains DNA from the cbhl locus with the entire cbhl coding sequence removed therefrom, and replaced with a T.reesei gene which acts as a selectable marker for transformation.
  • the present invention is directed towards the preparation of a particular plasmid, part of which plasmid is homologous to the T ⁇ reesei strain and contains the cbh2 gene from the T.reesei strain with almost the entire cbh2 coding sequence removed therefrom and replaced with a T.reesei gene which acts as a selectable marker for transformation.
  • the present invention is directed towards the preparation of a particular plasmid part of which plasmid is homologous to the T ⁇ reesei strain and contains the eq!3 gene from the T.reesei strain with the egl3 coding sequence disrupted by insertion of a T.reesei gene which acts as a selectable marker for transformation.
  • the e ⁇ !3 locus codes for the EGII protein.
  • the present invention is directed towards the preparation of a particular plasmid part of which plasmid is homologous to the T ⁇ reesei strain and contains the e ⁇ il gene from the T.reesei strain with part of the egll coding sequence removed therefrom and replaced with a T.reesei gene which acts as a selectable marker for transformation.
  • the present invention is directed towards the preparation of a particular plasmid part of which contains DNA from the cbhl locus with the entire cbhl coding sequence removed therefrom and replaced with the egll gene from - reesei and a T ⁇ reesei gene which acts as a selectable marker for transformation.
  • the present invention is directed towards the preparation of a particular plasmid part of which plasmid is homologous to the T ⁇ reesei strain and contains a xylanase gene from the T. reesei strain and a T. reesei gene which acts as a selectable marker for transformation.
  • FIG. 1 is an outline of the construction of p ⁇ CBHIp_ ⁇ r4.
  • FIG. 2 illustrates deletion of the T. reesei gene by integration of the larger EcoRI fragment from p ⁇ CBHIp_ ⁇ r4 at the cbhl locus on one of the _ reesei chromosomes.
  • Fid. 3 is an autoradiograph of DNA from T ⁇ reesei strain GC69 transformed with EcoRI digested p ⁇ CBHIp_yr4 after Southern blot analysis using a 32 P labelled p ⁇ CBHip_ ⁇ r4 as the probe. The sizes of molecular weight markers are shown in kilobase pairs to the left of the Figure.
  • FIG. 4 is an autoradiograph of DNA from a T ⁇ reesei strain GC69 transformed with EcoRI digested p ⁇ CBHIp_ ⁇ r4 using a 32 P labelled plntCBHI as the probe.
  • the sizes of molecular weight markers are shown in kilobase pairs to the left of the Figure.
  • FIG. 5 is an isoelectric focusing gel displaying the proteins secreted by the wild type and by transformed strains of T ⁇ reesei.
  • Lane A of the isoelectric focusing gel employs partially purified CBHI from T ⁇ reesei:
  • Lane B employs a wild type T ⁇ reesei :
  • Lane C employs protein from a T ⁇ reesei strain with the cbhl gene deleted;
  • Lane D employs protein from a T ⁇ reesei strain with the cbhl and cbh2 genes deleted.
  • the right hand side of the figure is marked to indicate the location of the single proteins found in one or more of the secreted proteins.
  • BG refers to the ⁇ - glucosidase
  • E1 refers to endoglucanase I
  • E2 refers to endoglucanase II
  • E3 refers to endoglucanase III
  • C1 refers to exo-cellobiohydrolase I
  • C2 refers to exo-cellobiohydrolase II.
  • FIG. 6A is a representation of the T. reesei cbh2 locus, cloned as a 4.1 kb EcoRI fragment on genomic DNA and FIG. 6B is a representation of the cbh2 gene deletion vector pP ⁇ CBHII.
  • FIG. 7 is an autoradiograph of DNA from T. reesei strain P37P ⁇ CBHIPyr " 26 transformed with EcoRI digested pP ⁇ CBHIl after Southern blot analysis using a 32 P labelled pP ⁇ CBHIl as the probe. The sizes of molecular weight markers are shown in kilobase pairs to the left of the Figure.
  • FIG. 8 is a diagram of the plasmid pEGIpyr4.
  • FIG. 9 is a diagram of the site specific alterations made in the egll and cbhl genes to create convenient restriction endonuclease cleavage sites.
  • the upper line shows the original DNA sequence
  • the changes introduced are shown in the middle line
  • the new sequence is shown in the lower line.
  • FIG. 10 is a diagram of the larger EcoRI fragment which can be obtained from pCEPCl .
  • FIG. 1 1 is an autoradiograph of DNA, from an untransformed strain of T. reesei RutC30 and from two transformants obtained by transforming L. reesei with EcoRI digested pCEPCl .
  • the DNA was digested with Pstl.
  • a Southern blot was obtained and hybridized with 32 P labelled pUC4K::cbh1. The sizes of marker DNA fragments are shown in kilobase pairs to the left of the Figure.
  • FIG. 12 is a diagram of the plasmid pEGII::P-1.
  • FIG 13. is an autoradiograph of DNA from T. reesei strain P37P ⁇ 67P " 1 transformed with Hindlll and BamHI digested pEGII::P-1.
  • a Southern blot was prepared and the DNA was hybridized with an approximately 4kb Pstl fragment of radiolabelled T.reesei DNA containing the e ⁇ !3 gene.
  • Lanes A, C and E contain DNA from the untransformed strain whereas, Lanes B, D and F contain DNA from the untransformed L reesei strain.
  • the T.reesei DNA was digested with B ⁇ lll in Lanes A and B, with EcoRV in Lanes C and D and with Pstl in Lanes E and F.
  • the size of marker DNA fragments are shown in kilobase pairs to the left of the Figure.
  • FIG. 14 is a diagram of the plasmid pP ⁇ EGI-1 .
  • FIG. 15 is an autoradiograph of a Southern blot of DNA isolated from transformants of strain GC69 obtained with Hindlll digested p ⁇ EGIpyr-3.
  • the pattern of hybridisation with the probe, radiolabelled p ⁇ EGIpyr-3, expected for an untransformed strain is shown in Lane C.
  • Lane A shows the pattern expected for a transformant in which the egll gene has been disrupted
  • Lane B shows a transformant in which p ⁇ EGIpyr-3 DNA has integrated into the genome but without disrupting the e ⁇ ll gene.
  • Lane D contains p ⁇ EGIpyr-3 digested with Hindlll to provide appropriate size markers. The sizes of marker DNA fragments are shown in kilobase pairs to the right of the figure.
  • FIG. 16 shows alignment of the deduced amino acid sequence of the cloned T ⁇ reesei genes with the sequence of other microbial xylanases.
  • "High pi” indicates the sequence of the high pi xylanase of - reesei.
  • Low pi the sequence of Low pi xylanase of T ⁇ reesei, "trichv” the sequence of a T ⁇ viride xylanase disclosed by M.
  • homologous DNA means that the DNA contains no DNA sequences from a microorganism other than T. reesei.
  • substantially homologous recombinant DNA means the recombinant DNA is derived from T. reesei or is synthesized to conform to the DNA sequence in T. reesei and contains no more than 50 base pairs of contiguous synthetic DNA. More preferably, the recombinant DNA is derived from T.reesei or is synthesized to conform to the DNA sequence of T.reesei and contains no more than 25 base pairs of contiguous synthetic DNA. According to current guidelines "incorporation of fully sequenced DNA of 25 base pairs or less is not considered to comprise modifications to host vector systems.” (U.S. Department of Health, Education, and Welfare, Public Health Service, National Institute of Health. Modification of Certified Host-Vector Systems. Recombinant-DNA Technical Bulletin 2 (3): 132, 1979).
  • heterologous DNA means any source of DNA that is nonsynthetically produced from a microorganism other than T. reesei or any piece of synthetic DNA greater than 50 base pairs not synthesized to conform to the DNA sequence of T. reesei.
  • Heterologous protein means protein encoded by heterologous DNA.
  • homologous recombination means that the recombinant DNA integrated at a specific location within the genome which has the same DNA sequence as part of the recombinant DNA and did not integrate at secondary sites.
  • Endoglucanase (EG) components refer to all of those fungal cellulase components or combination of components which are the endoglucanase components of T. reesei (specifically , EGI, EGII, EGIII, and the like, either alone or in combination).
  • exo-cellobiohydrolase CBH components
  • CBH components refer to those fungal cellulase components which are the exo-cellobiohydrolase components of T. reesei (specifically CBHI, CBHII and the like, either alone or in combination).
  • cells means both the cells and the protoplasts created from the cells of T. reesei.
  • overexpress means that an additional copy of a gene has been integrated into the genome so that when the protein encoded by the gene is expressed, the protein is produced at quantities greater than if only one copy of the gene was present in the genome.
  • the present invention relates to the precise replacement of chromosomal regions with DNA sequences that may or may not be altered in vitro by using recombinant DNA techniques. Total gene replacement in the transformed host microorganism is possible. It is further contemplated by the present invention, that the native cbhl . cbh2, egll , or e ⁇ .13 genes, or any other cloned T. reesei gene can be altered, such as a deletion or deletions of specific nucleic acids within the gene by techniques known in this art and used to replace the natural gene in the transformed microorganism. For example, amino acids that are present at the catalytic site of the protein may be deleted or substituted with different amino acids. These ]n vitro altera- tions may produce cellulase proteins that have altered specific activity with certain substrates, altered end product inhibition, altered sensitivity to oxidation and/or altered temperature or pH activity profiles for the enzyme.
  • T. reesei is a mesophilic, saprophytic filamentous fungus which secretes different cellulolytic enzymes
  • the transformants can be used to produce the desired cellulase enzyme or combination of enzymes thereof.
  • the present invention is not limited to gene manipulation of only cellulolytic enzymes. Any alteration of any gene in the fungus T. reesei is contemplated by the present invention and any T.
  • reesei gene which has been cloned can be deleted from the genome or be disrupted, including, but not limited to cbhl . cbh2. egll . eg!3. genes encoding other endoglucanases, ⁇ -glucosidase or xylanases or other carbohydrases, genes required for uridine biosynthesis (eg. oyr4) arginine biosynthesis, tryptophan biosynthesis and the like. Multiple deletions are aiso possible, such as deletions of both the cbhl and cbh2 genes both the e ⁇ ll and e ⁇ !3 genes, and of the cbhl . cbh2. e ⁇ H and e ⁇ !3 genes.
  • a selectable marker must first be chosen so as to enable detection of the transformed fungus. Any selectable marker gene which is naturally present in T ⁇ reesei. can be used in the present invention so that its presence in the transformants will not materially affect the properties thereof.
  • the selectable marker can be a gene which encodes an assayable product.
  • the selectable marker may be a functional copy of a T ⁇ reesei gene which, if lacking in the host strain results in the host strain displaying an auxotrophic phenotype.
  • the selectable marker may be derived from a T. reesei gene which specifies a novel phenotype such as an ability to utilize a metabolite that is usually not metabolized by T.
  • the host strains used could be derivatives of T. reesei which lack or have a nonfunctional gene or genes corresponding to the selectable marker chosen.
  • a selectable marker of pyr4 is used, then a specific pyr ' derivative strain is used as a recipient in the transformation procedure.
  • Other examples of selectable markers that can be used in the present invention include the T_. reesei genes equivalent to the Asperoillus nidulans genes argB. trpC. ⁇ iaD. and the like.
  • the corresponding recipient strain must therefore be a derivative strain such as ar ⁇ B ' . TrpC. niaD ' , and the like.
  • the strain is derived from a starting host strain which is any T. reesei strain. However it is preferable to use a T. reesei over ⁇ producing strain such as RL-P37, described by Sheir-Neiss et al. in Appl. Microbiol. Biotechnology, 20 (1984) pp. 46-53, since this strain secretes elevated amounts of proteins and in particular elevated amounts of cellulase enzymes. This strain is then used to produce the derivative strains used in the transformation process.
  • the derivative strain of T. reesei can be prepared by a number of techniques known in the art such as the filtration enrichment technique described by Nevalainen which is incorporated herein by reference
  • argB- derivatives can be identified by using a series of minimal plates supplied by different intermediates in arginine biosynthesis.
  • Another example is the production of pyr4- derivative strains by subjecting the strains to fluoroorotic acid (FOA).
  • FAA fluoroorotic acid
  • the pyr4 gene encodes orotidine- ⁇ '-monophosphate decarboxylase, an enzyme required for the biosynthesis of uridine. Strains with an intact pyr4 gene grow in a medium lacking uridine but are sensitive to fluoroorotic acid.
  • pyr4- derivative strains which lack a functional orotidine monophosphate decarboxylase enzyme and require uridine for growth by selecting for FOA resistance.
  • FOA selection technique it is also possible to obtain uridine requiring strains which lack a functional orotate pyrophosphoribosyl transferase. It is possible to transform these cells with a functional copy of the gene encoding this enzyme (Berges and Barreau, 1991 , Curr. Genet. 19 pp359-365). Since it is easy to select derivative strains using the FOA resistance technique in the present invention, it is preferable to use the pyr4 gene as a selectable marker.
  • Any plasmid can be used in the present invention for the cloning of the selectable marker such as pUC-derivatives, pBR322 and the like.
  • the plasmid used is chosen on the basis of the convenience of restriction enzyme sites that permit the incorporation of the selectable marker into the plasmid with ease.
  • the selectable marker is then cloned into the respective plasmid using techniques known in the art, which techniques are set forth in Maniatis et al. (1989), and is incorporated herein by reference.
  • the pyr4 gene of T. reesei can be cloned into the pUC18 plasmid by the methods described by Smith et al. (1991 ).
  • a region of the T. reesei genome which encompasses the coding sequence of the gene to be deleted from the T. reesei strain through transformation is then cloned into a second plasmid by methods known in the art.
  • Any gene from the strain T. reesei which has been cloned can be deleted such as cbhl . cbh2. eoll . eql3 and the like.
  • the addition of extra copies of a gene is also possible. For instance, a transformant may be desired that has extra copies of the egll gene.
  • the present invention encompasses methods to also add these additional copies of the gene or genes.
  • the plasmid for gene deletion and/or addition is selected such that restriction enzyme sites are present therein to enable the fragment of homologous DNA to be removed as a single linear piece.
  • restriction enzyme sites are present therein to enable the fragment of homologous DNA to be removed as a single linear piece.
  • the desired gene that is to be deleted from the transformant is inserted into the plasmid by methods known in the art.
  • the plasmid containing the gene to be deleted or disrupted is then cut at the appropriate restriction enzyme site(s), the gene coding sequence or part thereof may be removed therefrom and the selectable marker inserted. Flanking DNA sequences from the locus of the gene to be deleted or disrupted, preferably between about 0.5 to 2.0 kb, remain on either side of the selectable marker gene. If the flanking region is too small, then homologous integration occurs infrequently during transformation.
  • a preferred embodiment for preparing appropriate plasmid vectors utilizes the E. cpjj. vector plasmids pUC4K and pUC18.
  • the pUC4K plasmid vector has the cbhl gene which was originally obtained from genomic DNA of the T. reesei strain RL-P37 by hybridization with an appropriate oligonucleotide probe designed on the basis of the published sequence for the cbhl gene.
  • the cbhl gene was inserted into the pUC4K vector by cutting the vector with Pstl. resulting in the removal of the Kan r gene therefrom and ligating with a Pstl fragment of T ⁇ reesei DNA containing the cbhl gene.
  • pUC4K::cbhl The result ⁇ ing plasmid, pUC4K::cbhl was cut with Hindlll and the larger fragment of about 6 kb was isolated and religated to produce plasmid pUC4K::cbhl ⁇ H/H. This procedure removed the entire cbhl coding sequence and approximately 1.2 kb upstream and 1 .5 kb downstream flanking sequences. Approximately 1 kb of flanking DNA from either end of the original Pstl fragment remains.
  • the plasmid pUC4K::cbhl ⁇ H/H was cut with Hindlll and the ends were dephosphorylated with calf intestinal alkaline phosphatase to prevent self-ligation of the vector.
  • This DNA was then ligated with a 6.5 kb Hindlll pyr4 gene fragment to create P ⁇ CBHIPV ⁇ 4.
  • a much smaller fragment of DNA bearing the pyr4 gene also can be used.
  • FIG. 6A Another preferred embodiment for preparing appropriate plasmid vectors in the present invention is diagrammatically illustrated in FIG. 6A.
  • the cbh2 gene of T. reesei. encoding the CBHII protein has been cloned as a 4.1 kb EcoRI fragment of genomic DNA (Chen et al., 1987).
  • the plasmid pP ⁇ CBHIl has been constructed in which a 1 .7 kb central region of the cbh2 gene between a Hindlll site and a Clal site has been removed and replaced with the T. reesei pyr4 gene.
  • a plasmid has been constructed that contains the T.
  • a plasmid, pCEPCl also has been constructed in which the promotor from the cbhl gene has been fused to the coding sequence of the eoll gene, while maintaining the egll terminator region.
  • the 3' flanking region of the cbhl locus follows the egll terminator region.
  • the pyr4 gene is inserted into the 3' flanking region of the cbhl locus.
  • FIG. 12 Another preferred embodiment for preparing appropriate plasmid vectors in the present invention is diagrammatically illustrated in FIG. 12.
  • the eg!3 gene of T. reesei. encoding the EGII protein has been cloned as a 4 kb Pstl-Xhol fragment of genomic DNA ( Saloheimo et al., 1988, Gene 63. p.1 1-21 ).
  • the plasmid pEGII::P-1 has been constructed in which a 2.7 kb Sail fragment containing theT. reesei pyr4 gene was inserted into a Sail site within the EGII coding sequence resulting in disruption of the EGII coding sequence.
  • FIG. 14 Another preferred embodiment for preparing appropriate plasmid vectors in the present invention is diagrammatically illustrated in FIG. 14.
  • the e ⁇ l1 gene of T. reesei. encoding the EGI protein has been cloned as a 4.2 kb Hindlll fragment of genomic DNA (Pentilla et al., 1986, Gene 45, pp. 253-263; van Arsdell et al., 1987, BioTechnolo ⁇ v 5_, pp. 60-64).
  • the plasmid pP ⁇ EGI-1 has been constructed in which a 1 kb region from the center of the EGI coding sequence to a position beyond the 3' end of the coding sequence was removed and replaced with the T. reesei pyr4 gene.
  • the specific plasmids were linearized with restriction enzymes to produce an homologous DNA fragment containing the selectable marker.
  • the marker is preferably between two flanking regions which act to integrate the selectable marker at a precise locus in the derivative T. reesei strain during the transformation process.
  • the transforming DNA may sometimes integrate into secondary sites, transformants in which only a single copy of the linear DNA integrated into the desired locus can be identified by methods described in the specific examples given below.
  • T. reesei strain can be deleted and replaced in the T. reesei strain using the above techniques. Any available selectable markers can be used, as discussed below. Potentially any T. reesei gene which has been cloned, and thus identified, can be deleted from the genome using the above- described strategy. For instance, the cbhl . cbh2. egll and eg!3 genes can be deleted and replaced by a selectable marker gene. All of these variations are included within the present invention.
  • T. reesei Since the permeability of the cell wall in T. reesei is very low, uptake of the desired DNA sequence, gene or gene fragment is at best minimal. There are a number of methods to increase the permeability of the T. reesei cell wall in the derivative strain (i.e., lacking a functional gene corresponding to the used selectable marker) prior to the transformation process.
  • alkali metal ions and/or alkaline earth metal ions to a high concentration to T. reesei cells.
  • Any alkali metal or alkaline earth metal may be used in the present invention, however it is preferable to use either CaCI 2 or lithium acetate and more preferable to use lithium acetate.
  • the concentration of the alkali metal or alkaline earth metal may vary depending on the ion used. Generally between about 0.05 M to 0.4 M concentrations of alkali metal ions are used. It is preferable to use about a 0.1 M concentration of alkali earth metals. Preferably the lithium acetate concentration is about 0.1 M.
  • Another method that can be used to induce cell wall permeability to enhance DNA uptake in T. reesei is to resuspend the cells in a growth medium supplemented with sorbitol and carrier calf thymus DNA. Glass beads are then added to the supplemented medium and the mixture is vortexed at high speed for about 30 seconds. This treatment disrupts the cell walls, but may kill many of the cells.
  • T. reesei for transformation involves the preparation of protoplasts from fungal mycelium.
  • the mycelium can be obtained from germinated vegetative spores.
  • the mycelium is treated with an enzyme which digests the cell wall resulting in protoplasts.
  • the protoplasts are then protected by the presence of an osmotic stabilizer in the suspending medium.
  • These stabilizers include sorbitol, mannitol, potassium chloride, magnesium sulfate and the like.
  • concentration of these stabilizers varies between 0.8 M to 1.2 M. it is preferable to use about a 1.2 M solution of sorbitol in the suspension medium.
  • Uptake of the DNA into the host T. reesei strain is dependent upon the calcium ion concentration. Generally between about 10 mM CaCI 2 and 50 mM CaCI 2 is used in an uptake solution. Besides the need for the calcium ion in the uptake solution, other items generally included are a buffering system such as TE buffer (10 mM Tris, pH 7.4; 1 mM EDTA) or 10 mM MOPS, pH 6.0 buffer
  • polyethylene glycol acts to fuse the cell membranes thus permitting the contents of the medium to be delivered into the cytoplasm of the T. reesei strain and the plasmid DNA is transferred to the nucleus. This fusion frequently leaves multiple copies of the plasmid DNA tandemly integrated into the host chromosome.
  • a suspension containing the T. reesei protoplasts or cells that have been subjected to a permeability treatment at a density of 10 8 to 10 9 /ml, preferably 2 x 10 8 /ml are used in transformation.
  • These protoplasts or cells are added to the uptake solution, along with the desired linearized selectable marker having substantially homologous flanking regions on either side of said marker to form a transformation mixture.
  • a high concentration of PEG is added to the uptake solution. From 0.1 to 1 volume of 25% PEG 4000 can be added to the protoplast suspension. However, it is preferable to add about 0.25 volumes to the protoplast suspension.
  • Additives such as dimethyl sulfoxide, heparin, spermidine, potassium chloride and the like may also be added to the uptake solution and aid in transformation.
  • the mixture is then incubated at approximately 0°C for a period between 10 to 30 minutes. Additional PEG is then added to the mixture to further enhance the uptake of the desired gene or DNA sequence.
  • the 25% PEG 4000 is generally added in volumes of 5 to 15 times the volume of the transformation mixture; however, greater and lesser volumes may be suitable.
  • the 25% PEG 4000 is preferably about 10 times the volume of the transformation mixture.
  • the transformation mixture is then incubated at room temperature before the addition of a sorbitol and CaCI 2 solution.
  • the protoplast suspension is then further added to molten aliquots of a growth medium. This growth medium permits the growth of transformants only. Any growth medium can be used in the present invention that is suitable to grow the desired transformants. However, if Pyr* transformants are being selected it is preferable to use a growth medium that contains no uridine. The subsequent colonies are transferred and purified on a growth medium depleted of uridine.
  • the transformant produced by using the linear DNA fragment from p ⁇ CBHIpyr4 is strain P37P ⁇ CBHI. This strain has the cbhl gene deleted.
  • FIG. 2 illustrates diagrammati ⁇ cally a deletion of the T. reesei cbhl gene by integration of the larger EcoRI fragment from p ⁇ CBHIp_ ⁇ r4 at the cbhl locus on one of the Tj. reesei chromosomes.
  • the linear DNA fragment from p ⁇ CBHIpyr4 can be used to transform a I. reesei strain in which other cellulase component genes have been deleted or overexpressed in order to create a transformant in which at least the cbhl gene has been deleted.
  • a linearized substantially homologous DNA fragment can be prepared containing flanking DNA sequences from the T. reesei cbh2 locus located on either side of the T. reesei pyr4 gene.
  • transformation of GC69, a oyr4 ⁇ derivative, with the linear fragment will result in a transformant having the cbh2 gene deleted.
  • transformation of a pyr4 ' derivative of P37P ⁇ CBHI with the linear fragment and selection for growth on medium lacking uridine will result in a transformant having both the cbhl and cbh2 genes deleted.
  • the linear DNA fragment can be used to transform a T.
  • a linearized substantially homologous DNA fragment can be prepared encoding the egll locus with a part of the coding sequence replaced with the T. reesei pyr4 gene.
  • transformation of GC69, with the linear DNA fragment will result in a transformant having the eoll gene deleted.
  • the linear DNA fragment can be used to transform a T.
  • a linearized substantially homologous DNA fragment can be prepared encoding the eo!3 locus with the eo!3 coding sequence disrupted by the insertion of the I. reesei pyr4 gene.
  • transformation of GC69, with the linear fragment will result in a transformant having the eg!3 gene deleted.
  • the linear DNA fragment can be used to transform a T. reesei pvr ' strain in which other cellulase component genes have been deleted or overexpressed in order to create a transformant in which at least the eg!3 gene has been deleted.
  • Such transformants will be unable to produce the EGII component of cellulase derived from I. reesei.
  • a linearized substantially homologous DNA fragment containing a promotor from the cbhl gene can be fused to the coding sequence of an eoll gene.
  • the pyr4 ' gene and the 3' flanking region from the cbhl are then ligated to the fragment.
  • transformation of a T. reesei pyr4 ' strain with a linear fragment from pCEPCl containing the egll gene and selection for growth in the absence of uridine should result in a transformant containing a copy of the eoll gene under the control of the cbhl promotor at the cbhl locus, in addition to the native egll gene.
  • the linear DNA fragment from pCEPCl can be used to transform a T. reesei pyr ' strain in which other cellulase component genes have been deleted or overexpressed in order to create a transformant in which a number of cellulase components have been deleted and in which at least the egll gene is being overexpressed.
  • a linearized substantially homologous DNA fragment containing either the T.reesei low pi or high pi xylanase gene and a T.reesei selectable marker can be prepared. Transformation of T.reesei cells with this DNA fragment should result in transformants which overexpress a xylanase protein.
  • the transformants are then further cultured.
  • the secreted proteins from the transformed culture can then be obtained and used in a cellulase composition, which composition lacks the deleted proteins and/or contains the enhanced proteins.
  • the microorganisms modified in the above manner are particularly useful in preparing cellulase compositions having one or more deleted components.
  • such cellulase compositions impart improved properties per specific application as compared to cellulases containing naturally occurring ratios of EG components to CBH components.
  • cellulase compositions deficient in CBHI components and preferably deficient in CBHI and CBHII components, are useful in detergent cleaning compositions, e.g.,- laundry detergent compositions, and provide for improved color restoration, softening, etc. while providing reduced strength loss to cotton-containing fabrics. See, for instance U.S. Patent Application Serial No. 07/713,738 which is incorporated herein by reference in its entirety.
  • Such EG enriched cellulase compositions contain some CBHI components (but less than 5 weight percent based on the total weight of the cellulase composition), then such cellulase compositions also impart cleaning. Even more suprising is the fact that CBHII cellulase components do not substitute for CBHI cellulase components (at the levels tested) in providing cleaning benefits when combined with EG-type components in detergent compositions.
  • CBHI enriched cellulase compositions i.e, having a ratio of CBHI to all EG components of greater than 5:1
  • EG compositions containing less than about 5 weight percent of CBHI components impart degradation resistance to the detergent composition as compared to detergent compositions containing whole cellulase systems.
  • U.S. Patent Application Serial No. 07/422,814, filed October 19, 1989, and U.S. Patent Application Serial No. 07/713,738 which are incorporated herein by reference in their entirety. That is to say that cotton fabrics treated with such cellulase compositions provide for less strength loss when treated over repeated washings as compared to the strength loss resulting from whole cellulase systems.
  • such cellulase compositions enriched or deficient in the CBHI component can be produced by selectively altering the ability of the microorganism to produce one or more of the cellulase components.
  • the EG cellulase having less than about 5 weight percent of CBHI component described herein can be prepared by modifying I. reesei in the manner described above so that this microorganism is unable to produce CBHI and preferably CBHI and CBHII components.
  • the modified microorganisms of this invention are particularly suitable for preparing such compositions because they produce cellulase compositions which lack all of the CBH components whereas prior art purification techniques cannot.
  • the EGIII component of T ⁇ reesei is useful in detergent compositions and, because of its high activity at pH 7 - 8, is particularly suited for use in neutral/alkaline detergent compositions. See, for example, U.S. Patent Application Serial No. 07/747,647 which is incorporated herein by reference.
  • One method for preparing a cellulase compostion enriched in EGIII is to delete CBHI, CBHII, EGI and EGII.
  • the CBHI deficient cellulase compositions are also useful in improving the feel and appearance of cotton fabrics and garments
  • the cellulase compositions not only improve the appearance of the cotton fabric but also impart improved softening and degradation resistance to the fabric as compared to whole cellulase compositions (systems).
  • the cellulase composition has a ratio of all EG components to all CBHI components of 5:1 and greater and is preferably free of CBHI components and more preferably free of all CBH components.
  • such cellulase compositions could be prepared by the methods described herein by the selective deletion of cellulase genes from T ⁇ reesei. ln order to further illustrate the present invention and advantages thereof, the following specific examples are given, it being understood that the same are intended only as illustrative and in nowise limitative.
  • the pyr4 gene encodes orotidine-5'-monophosphate decarboxylase, an enzyme required for the biosynthesis of uridine.
  • the toxic inhibitor 5-fluoroorotic acid (FOA) is incorporated into uridine by wild-type cells and thus poisons the cells.
  • FAA 5-fluoroorotic acid
  • cells defective in the pyr4 gene are resistant to this inhibitor but require uridine for growth. It is, therefore, possible to select for pyr4 derivative strains using FOA.
  • spores of T. reesei strain RL-P37 (Sheir-Neiss, G. and Montenecourt, B.S., Appl. Microbiol. Biotechnol. 20, p.
  • a cbhl gene encoding the CBHI protein was cloned from the genomic DNA of I. reesei strain RL-P37 by hybridization with an oligonucleotide probe designed on the basis of the published sequence for this gene using known probe synthesis methods (Shoemaker et al., 1983b).
  • the cbhl gene resides on a 6.5 kb Pstl fragment and was inserted into Pstl cut pUC4K (purchased from Pharmacia Inc., Piscataway, NJ) replacing the Kan r gene of this vector using techniques known in the art, which techniques are set forth in Maniatis et al., (1989) and incorporated herein by reference.
  • pUC4K::cbh1 The resulting plasmid, pUC4K::cbh1 was then cut with Hindlll and the larger fragment of about 6 kb was isolated and religated to give pUC4K::cbh1 ⁇ H/H (see FIG. 1 ). This procedure removes the entire cbhl coding sequence and approximately 1.2 kb upstream and 1 .5 kb downstream of flanking sequences. Approximately, 1 kb of flanking DNA from either end of the original Pstl fragment remains.
  • the I. reesei pyr4 gene was cloned as a 6.5 kb Hindlll fragment of genomic DNA in pUC18 to form pTpyr2 (Smith et al., 1991 ) following the methods of Maniatis et al., supra.
  • the plasmid pUC4K::cbhl ⁇ H/H was cut with Hindlll and the ends were dephosphorylated with calf intestinal alkaline phosphatase. This end dephosphorylated DNA was ligated with the 6.5 kb Hindlll fragment containing the I. reesei pyr4 gene to give p ⁇ CBHIpj ⁇ 4.
  • FIG. 1 illustrates the construction of this plasmid.
  • Mycelium was obtained by inoculating 100 ml of YEG (0.5% yeast extract, 2% glucose) in a 500 ml flask with about 5 x 10 7 . reesei GC69 spores (the PV ⁇ 4 ' derivative strain). The flask was then incubated at 37°C with shaking for about 16 hours. The mycelium was harvested by centrifugation at 2,750 x g.
  • the harvested mycelium was further washed in a 1.2 M sorbitol solution and resuspended in 40 ml of a solution containing 5 mg/ml Novozym R 234 solution (which is the tradename for a multicomponent enzyme system containing 1 ,3-alpha-glucanase, 1 ,3-beta-glucanase, laminarinase, xylanase, chitinase and protease from Novo Biolabs, Danbury, Ct.); 5 mg/ml MgSO 4 .7H 2 O; 0.5 mg/ml bovine serum albumin; 1.2 M sorbitol.
  • Novozym R 234 solution which is the tradename for a multicomponent enzyme system containing 1 ,3-alpha-glucanase, 1 ,3-beta-glucanase, laminarinase, xylanase, chitinase
  • the protoplasts were removed from the cellular debris by filtration through Miracloth (Calbiochem Corp, La Jolla, CA) and collected by centrifugation at 2,000 x g.
  • the protoplasts were washed three times in 1.2 M sorbitol and once in 1.2 M sorbitol, 50 mM CaCI 2 , centrifuged and resuspended at a density of approximately 2 x 10 8 protoplasts per ml of 1.2 M sorbitol, 50 mM CaCI 2 .
  • Example 3 200 ⁇ of the protoplast suspension prepared in Example 3 was added to 20 ⁇ of EcoRI digested p ⁇ CBHlpyr4 (prepared in Example 2) in TE buffer (10 mM Tris, pH 7.4; 1 mM EDTA) and 50 ⁇ of a polyethylene glycol (PEG) solution containing 25% PEG 4000, 0.6 M KCI and 50 mM CaCI 2 . This mixture was incubated on ice for 20 minutes. After this incubation period 2.0 ml of the above-identified PEG solution was added thereto, the solution was further mixed and incubated at room temperature for 5 minutes.
  • PEG polyethylene glycol
  • the protoplast/medium mixture was then poured onto a solid medium containing the same Vogel's medium as stated above. No uridine was present in the medium and therefore only transformed colonies were able to grow as a result of complementation of the pyr4 mutation of strain GC69 by the wild type pyr4 gene insert in p ⁇ CBHI ⁇ y_r_4. These colonies were subsequently transferred and purified on a solid Vogel's medium N containing as an additive, 1 % glucose and stable transformants were chosen for further analysis.
  • DNA was isolated from the transformants obtained in Example 4 after they were grown in liquid Vogel's medium N containing 1 % glucose. These transformant DNA samples were further cut with a Pstl restriction enzyme and subjected to agarose gel electrophoresis. The gel was then blotted onto a Nytran membrane filter and hybridized with a 32 P labelled p ⁇ CBHIfi ⁇ r4 probe. The probe was selected to identify the native cbhl gene as a 6.5 kb Pstl fragment, the native pyr4 gene and any DNA sequences derived from the transforming DNA fragment.
  • the radioactive bands from the hybridization were visualized by autoradiography.
  • the autoradiograph is seen in FIG. 3.
  • Five samples were run as described above, hence samples A, B, C, D, and E.
  • Lane E is the untransformed strain GC69 and was used as a control in the present analysis.
  • Lanes A-D represent transformants obtained by the methods described above.
  • the numbers on the side of the autoradiograph represent the sizes of molecular weight markers.
  • lane D does not contain the 6.5 kb CBHI band, indicating that this gene has been totally deleted in the transformant by integration of the DNA fragment at the cbhl gene.
  • the cbhl deleted strain is called P37P ⁇ CBHI.
  • Figure 2 outlines the deletion of the T.
  • sample A contained the cbhl gene, as indicated by the band at 6.5 kb; however the transformant, sample B, does not contain this 6.5 kb band and therefore does not contain the cbhl gene and does not contain any sequences derived from the pUC plasmid.
  • Spores from the produced P37P ⁇ CBHI strain were inoculated into 50 ml of a Trichoderma basal medium containing 1 % glucose, 0.14% (NH 4 ) 2 S0 4 , 0.2% KH 2 P0 4 , 0.03% MgSO 4 , 0.03% urea, 0.75% bactotryptone, 0.05% Tween 80, 0.000016% CuSO 4 .5H 2 O, 0.001 % FeSO 4 .7H 2 O, 0.000128% ZnSO 4 .7H 2 O, 0.0000054% Na 2 MoO 4 .2H 2 O, 0.0000007% MnCi.4H20).
  • the medium was incubated with shaking in a 250 ml flask at 37 °C for about 48 hours.
  • the resulting mycelium was collected by filtering through Miracloth (Calbiochem Corp.) and washed two or three times with 17 mM potassium phosphate.
  • the mycelium was finally suspended in 17 mM potassium phosphate with 1 mM sophorose and further incubated for 24 hours at 30°C with shaking.
  • the supernatant was then collected from these cultures and the mycelium was discarded.
  • Samples of the culture supernatant were analyzed by isoelectric focusing using a Pharmacia Phastgel system and pH 3-9 precast gels according to the manufacturer's instructions. The gel was stained with silver stain to visualize the protein bands.
  • the band corresponding to the cbhl protein was absent from the sample derived from the strain P37P ⁇ CBHI, as shown in FIG. 5.
  • This isoelectric focusing gel shows various proteins in different supernatant cultures of I. reesei. Lane A is partially purified CBHI; Lane B is the supernatant from an untransformed I. reesei culture; Lane C is the supernatant from strain P37P ⁇ CBHI produced according to the methods of the present invention. The position of various cellulase components are labelled CBHI, CBHII, EGI, EGII, and EGIII. Since CBHI constitutes 50% of the total extracellular protein, it is the major secreted protein and hence is the darkest band on the gel. This isoelectric focusing gel clearly shows depletion of the CBHI protein in the P37P ⁇ CBHI strain.
  • the cbh2 gene of T. reesei. encoding the CBHII protein has been cloned as a 4.1 kb EcoRI fragment of genomic DNA which is shown diagramatically in FIG. 6A (Chen et al., 1987, Biotechnology. 5:274-278). This 4.1 kb fragment was inserted between the EcoRI sites of pUC4XL.
  • the latter plasmid is a pUC derivative (constructed by R.M. Berka, Genencor International Inc.) which contains a multiple cloning site with a symetrical pattern of restriction endonuclease sites arranged in the order shown here: EcoRI. BamHI. Sacl. Smal. Hindlll. Xhol.
  • the I. reesei pyr4 gene was excised from pTpyr2 (see Example 2) on a 1.6 kb Nhel-Sohl fragment and inserted between the SphI and Xbal sites of pUC219 (see Example 16) to create p219M (Smith et al., 1991 , Curr. Genet 19 p. 27-33).
  • the PV ⁇ 4 gene was then removed as a Hindlll-Clal fragment having seven bp of DNA at one end and six bp of DNA at the other end derived from the pUC219 multiple cloning site and inserted into the Hindlll and Clal sites of the cbh2 gene to form the plasmid pP ⁇ CBHIl (see FIG. 6B). Digestion of this plasmid with EcoRI will liberate a fragment having 0.7 kb of flanking DNA from the cbh2 locus at one end, 1.7 kb of flanking DNA from the cbh2 locus at the other end and the T. reesei pyr4 gene in the middle.
  • Protoplasts of strain GC69 will be generated and transformed with EcoRI digested pP ⁇ CBHIl according to the methods outlined in Examples 3 and 4.
  • DNA from the transformants will be digested with EcoRI and Asp718, and subjected to agarose gel electrophoresis.
  • the DNA from the gel will be blotted to a membrane filter and hybridized with 32 P labelled pP ⁇ CBHIl according to the methods in Example 11 .
  • Transformants will be identified which have a single copy of the EcoRI fragment from pP ⁇ CBHIl integrated precisely at the cbh2 locus.
  • the transformants will also be grown in shaker flasks as in Example 7 and the protein in the culture supernatants examined by isoelectric focusing. In this manner T. reesei GC69 transformants which do not produce the CBHII protein will be generated.
  • Protoplasts of strain P37P ⁇ CBHIPyr " 26 were generated and transformed with EcoRI digested pP ⁇ CBHIl according to the methods outlined in Examples 3 and 4.
  • DNA was extracted from strain P37P ⁇ CBH67, digested with EcoRI and Asp718. and subjected to agarose gel electrophoresis. The DNA from this gel was blotted to a membrane filter and hybridized with 32 p labelled pP ⁇ CBHIl (FIG. 7).
  • Lane A of FIG. 7 shows the hybridization pattern observed for DNA from an untransformed T. reesei strain. The 4.1 kb EcoRI fragment containing the wild-type cbh2 gene was observed.
  • Lane B shows the hybridization pattern observed for strain P37P ⁇ CBH67. The single 4.1 kb band has been eliminated and replaced by two bands of approximately 0.9 and 3.1 kb. This is the expected pattern if a single copy of the EcoRI fragment from pP ⁇ CBHIl had integrated precisely at the cbh2 iocus.
  • the I. reesei egll gene which encodes EGI, has been cloned as a 4.2 kb Hindlll fragment of genomic DNA from strain RL-P37 by hybridization with oligonucleotides synthesized according to the published sequence (Penttila et al., 1986, Gene 45:253-263; van Arsdell et al., 1987, Bio/Technolo ⁇ v 5:60-64).
  • a 3.6 kb Hindlll-BamHI fragment was taken from this clone and ligated with a 1.6 kb Hindlll- BamHI fragment containing the I.
  • reesei pyr4 gene obtained from pTpyr2 (see Example 2) and pUC218 (identical to pUC219, see Example 16, but with the multiple cloning site in the opposite orientation) cut with Hindlll to give the plasmid PEGIPV ⁇ 4 (FIG. 8). Digestion of PEGIPV ⁇ 4 with Hindlll would liberate a fragment of DNA containing only T. reesei genomic DNA (the egll and oyr4 genes) except for 24 bp of sequenced, synthetic DNA between the two genes and 6 bp of sequenced, synthetic DNA at one end (see FIG. 8).
  • a pyr4 defective derivative of T. reesei strain RutC30 (Sheir- Neiss and Montenecourt, (1984), Appl. Microbiol. Biotechnol. 20:46- 53) was obtained by the method outlined in Example 1 . Protoplasts of this strain were transformed with undigested pEGIpyr4 and stable transformants were purified.
  • TSF medium 0.05M citrate-phosphate buffer, pH 5.0; Avicel microcrystalline cellulose, 10 g/l; KH 2 P0 4 , 2.0 g/l; (NH 4 ) 2 S0 4 , 1.4 g/l; proteose peptone, 1 .0 g/l; Urea, 0.3 g/l; MgSO 4 .7H 2 O, 0.3 g/l; CaCI 2 , 0.3 g/l; FeS0 4 .7H 2 0, 5.0 mg/l; MnS0 4 .H 2 0, 1.6 mg/l; ZnS0 4 , 1.4 mg/l; CoCI 2 , 2.0 mg/l; 0.1 % Tween 80).
  • TSF medium 0.05M citrate-phosphate buffer, pH 5.0; Avicel microcrystalline cellulose, 10 g/l; KH 2 P0 4 , 2.0 g/l; (NH 4 ) 2 S0 4 , 1.4 g/l; proteose peptone
  • the volume was finally adjusted to 100 ml with deionized water and sodium azide added to a final concentration of 0.02%.
  • Aliquots of I. reesei control culture, pEGI ⁇ r4 transformant culture supernatant or 0.1 M sodium acetate as a blank (10-20 ⁇ ) were placed in tubes, 250 ⁇ of substrate was added and the tubes were incubated for 30 minutes at 37°C.
  • the tubes were placed on ice for 10 minutes and 1 ml of cold precipitant (3.3% sodium acetate, 0.4% zinc acetate, pH 5 with HCl, 76% ethanol) was then added.
  • the tubes were vortexed and allowed to sit for five minutes before centrifuging for three minutes at approximately 13,000 x g.
  • the optical density was measured spectrophotometrically at a wavelength of 590-600 nm.
  • the protein assay used was the BCA (bicinchoninic acid) assay using reagents obtained from Pierce, Rockford, Illinois, USA.
  • the standard was bovine serum albumin (BSA).
  • BCA reagent was made by mixing 1 part of reagent B with 50 parts of reagent A.
  • One ml of the BCA reagent was mixed with 50 ⁇ of appropriately diluted BSA or test culture supernatant. Incubation was for 30 minutes at 37°C and the optical density was finally measured spectrophotometrically at a wavelength of 562 nm.
  • Table 1 The results of the assays described above are shown in Table 1 . It is clear that some of the transformants produced increased amounts of endoglucanase activity compared to untransformed strain RutC30.
  • endoglucanases and exo-cellobiohydrolases produced by untransformed T. reesei constitute approximately 20 and 70 percent respectively of the total amount of protein secreted. Therefore a transformant such as EP5, which produces approximately four-fold more endoglucanase than strain RutC30, would be expected to secrete approximately equal amounts of endoglucanase-type and exo-cellobiohydrolase-type proteins.
  • transformants described in this Example were obtained using intact pEGIpyr4 and will contain DNA sequences integrated in the genome which were derived from the pUC plasmid. Prior to transformation it would be possible to digest pEGIpyr4 with Hindlll and isolate the larger DNA fragment containing only T. reesei DNA.
  • Transformation of I. reesei with this isolated fragment of DNA would allow isolation of transformants which overproduced EGI and contained no heterologous DNA sequences except for the two short pieces of synthetic DNA shown in FIG. 8. It would also be possible to use pEGIpyr4 to transform a strain which was deleted for either the cbhl gene, or the cbh2 gene, or for both genes. In this way a strain could be constructed which would over-produce EGI and produce either a limited range of, or no, exo-cellobiohydrolases.
  • Example 13 The methods of Example 13 could be used to produce I. reesei strains which would over-produce any of the other cellulase components, xylanase components or other proteins normally produced by I. reesei.
  • a plasmid, pCEPCl was constructed in which the coding sequence for EGI was functionally fused to the promoter from the cbhl gene. This was achieved using in vitro, site-specific mutagenesis to alter the DNA sequence of the cbhl and eoll genes in order to create convenient restriction endonuclease cleavage sites just 5' (upstream) of their respective translation initiation sites. DNA sequence analysis was performed to verify the expected sequence at the junction between the two DNA segments. The specific alterations made are shown in FIG. 9.
  • a pyr4 defective strain of T ⁇ reesei RutC30 (Sheir-Neiss, supra) was obtained by the method outlined in Example 1. This strain was transformed with pCEPCl which had been digested with EcoRI. Stable transformants were selected and subsequently cultured in shaker flasks for cellulase production as described in Example 13. In order to visualize the cellulase proteins, isoelectric focusing gel electrophoresis was performed on samples from these cultures using the method described in Example 7. Of a total of 23 transformants analysed in this manner 12 were found to produce no CBHI protein, which is the expected result of integration of the CEPC1 DNA at the cbhl locus.
  • Southern blot analysis was used to confirm that integration had indeed occurred at the cbhl locus in some of these transformants and that no sequences derived from the bacterial plasmid vector (pUC4K) were present (see Fig. 1 1 ).
  • the DNA from the transformants was digested with Pstl before being subjected to electrophoresis and blotting to a membrane filter.
  • the resulting Southern blot was probed with radiolabelled plasmid pUC4K::cbh1 (see Example 2).
  • the probe hybridised to the cbhl gene on a 6.5 kb fragment of DNA from the untransformed control culture (FIG. 1 1 , lane A).
  • Endoglucanase activity assays were performed on samples of culture supernatant from the untransformed culture and the transformants exactly as described in Example 13 except that the samples were diluted 50 fold prior to the assay so that the protein concentration in the samples was between approximately 0.03 and 0.07 mg/ml.
  • the results of assays performed with the untransformed control culture and four different transformants are shown in Table 2.
  • Transformants CEPC1 -103 and CEPC1 -1 12 are examples in which integration of the CEPC1 fragment had led to loss of CBHI production.
  • the eo!3 gene encoding EGII (previously referred to as EGIII by others), has been cloned from T. reesei and the DNA sequence published (Saloheimo et al., 1988, Gene 63:1 1-21 ).
  • the latter vector, pUC219 is derived from pUC1 19 (described in Wilson et al., 1989, Gene 77:69-78) by expanding the multiple cloning site to include restriction sites for Bglll, Clal and Xhol.
  • T. reesei strain GC69 will be transformed with pEGII::P-1 which had been previously digested with Hindlll and BamHI and stable transformants will be selected. Total DNA will be isolated from the transformants and Southern blot analysis used to identify those transformants in which the fragment of DNA containing the pyr4 and eol3 genes had integrated at the eg!3 locus and consequently disrupted the EGII coding sequence. The transformants will be unable to produce EGII. It would also be possible to use pEGII::P-1 to transform a strain which was deleted for either or all of the cbhl . cbh2. or eoll genes. In this way a strain could be constructed which would only produce certain cellulase components and no EGII component.
  • a pyr4 deficient derivative of strain P37P ⁇ CBH67 was obtained by the method outlined in Example 1.
  • This strain P37P ⁇ 67P " 1 was transformed with pEGII::P-1 which had been previously digested with Hindlll and BamHI and stable transformants were selected.
  • Total DNA was isolated from transformants and Southern blot analysis used to identify strains in which the fragment of DNA containing the pyr4 and eg!3 genes had integrated at the eg!3 locus and consequently disrupted the EGII coding sequence.
  • the size of the band corresponding to the eo!3 gene increased in size by approximately 2.7 kb (the size of the inserted pyr4 fragment) between the untrarisformed P37P ⁇ 67P ' 1 strain (Lanes A and C) and the transformant disrupted for eg!3 (FIG. 13, Lanes B and D).
  • the transformant containing the disrupted eg!3 gene illustrated in FIG. 13 was named A22.
  • the transformant identified in FIG. 13 is unable to produce CBHI, CBHII or EGII.
  • the eoll gene of T. reesei strain RL-P37 was obtained, as described in Example 12, as a 4.2 kb Hindlll fragment of genomic DNA. This fragment was inserted at the Hindlll site of pUC100 (a derivative of pUC18; Yanisch-Perron et al., 1985, Gene 33: 103-1 19, with an oligonucleotide inserted into the multiple cloning site adding restriction sites for BgJ.ll, Clal and Xhol).
  • the plasmid pP ⁇ EGI-1 can be digested with Hindlll to release a DNA fragment comprising only T. reesei genomic DNA having a segment of the egll gene at either end and the pyr4 gene replacing part of the EGI coding sequence, in the center.
  • Example 19 The expectation that the EGI gene could be inactivated using the method outlined in Example 19 is strengthened by this experiment.
  • a plasmid, p ⁇ EGIpyr-3 was constructed which was similar to pP ⁇ EGI-1 except that the Asperoillus niger pyr4 gene replaced the Ii reesei pyr4 gene as selectable marker.
  • the egll gene was again present as a 4.2 kb Hindlll fragment inserted at the Hindlll site of pUCI OO.
  • the same internal 1 kb EcoRV fragment was removed as during the construction of pP ⁇ EGI-1 (see Example 19) but in this case it was replaced by a 2.2 kb fragment containing the cloned A.
  • nioer oyrG gene (Wilson et al., 1988, Nucl. Acids Res. 16 p.2339). Transformation of a pyr4 deficient strain of _ reesei (strain GC69) with p ⁇ EGIpyr-3, after it had been digested with Hindlll to release the fragment containing the pyrG gene with flanking regions from the eoll locus at either end, led to transformants in which the eoll gene was disrupted. These transformants were recognized by Southern blot analysis of transformant DNA digested with Hindlll and probed with radiolabelled p ⁇ EGIpyr-3.
  • FIG. 15, lane C In the untransformed strain of T ⁇ reesei the eg 11 gene was present on a 4.2 kb Hindlll fragment of DNA and this pattern of hybridization is represented by Fig. 15, lane C. However, following deletion of the eoll gene by integration of the desired fragment from p ⁇ EGIpyr-3 this 4.2 kb fragment disappeared and was replaced by a fragment approximately 1.2 kb larger in size, FIG. 15, lane A. Also shown in FIG. 15, lane B is an example of a transformant in which integration of a single copy of pP ⁇ EGIpyr-3 has occurred at a site in the genome other than the eoll locus.
  • a pyr4 deficient derivative of strain A22 (from Example 18) wil be obtained by the method outlined in Example 1 .
  • This strain will be transformed with pP ⁇ EGI-1 which had been previously digested with Hindlll to release a DNA fragment comprising only I, reesei genomic DNA having a segment of the eoll gene at either end with part of the EGI coding sequence replaced by the oyr4 gene.
  • Stable pyr4+ transformants will be selected and total DNA isolated from the transformants.
  • the DNA will be probed with 32 P labelled pP ⁇ EGI-1 after Southern blot analysis in order to identify transformants in which the fragment of DNA containing the pyr4 gene and egll sequences has integrated at the eoll locus and consequently disrupted the EGI coding sequence.
  • the transformants identified will be unable to produce CBHI, CBHII, EGI and EGII.
  • xylanase enzymes from _ reesei were purified starting with CYTOLASE 123TM (a complete fungal cellulase enzyme composition obtained from _T ⁇ reesei and available from Genencor International, Inc., South San Francisco, CA).
  • the substrate used in assays for xylanase activity was 4-O-Methyl-D-glucurono-D-xylan Remazol Brilliant Blue R (MegaZyme, North Rocks, N.S.W., Australia). Fractionations were done using columns containing the following resins: Sephadex G-25 gel filtration resin (Sigma Chemical Company, St.
  • QA Trisacryl M anion exchange resin and SP Trisacryl M cation exchange resin IBF Biotechnics, Savage, MD.
  • Each xylanase protein was precipitated by the addition of 0.9 ml of acetone to 0.1 ml of enzyme solution (at a concentration of 1 mg/ml) and incubation at -20°C for 10 minutes. The protein was collected by centrifugation and the pellet dried and resuspended in 0.05 ml of 100 mM Tris with the pH adjusted to 8.0 with TFA (trifluoroacetic acid) and 2M urea. Five ⁇ g of trypsin/chymotrypsin was added and the mixture incubated at 37°C for four hours.
  • a degenerate pool of oligonucleotides was made corresponding to a region (Tyr lie Met Glu Asp Asn His Asn Tyr) within one of the sequenced peptides.
  • Southern blots of L. reesei genomic DNA digested with Hindlll and other restriction enzymes were probed with the 32 P labelled oligonucleotide pool.
  • a 2 kb Hindlll fragment was observed to hybridize with the oligonucleotide pool.
  • the 2 kb Hindlll fragment was isolated from a plasmid bank of T_. reesei Hindlll fragments contained in pUC219 using the radioactively labelled oligonucleotide pool as a probe.
  • DNA sequencing near one end of the 2 kb Hindlll fragment revealed a translated protein sequence that was identical to the entire sequence obtained from one of the peptides (peptide 1 ) from the low pi xylanase protein. Another translated protein sequence close to the previous sequence was found to be highly similar to the protein sequence from two different xylanase enzymes from a Bacillus species.
  • the radioactively labelled 2 kb Hindlll fragment was used as a probe in Southern blots of restriction enzyme-digested J__. reesei genomic DNA to construct a restriction map of the region around the 2 kb Hindlll fragment.
  • Preliminary DNA sequence data when converted to a protein sequence, shows extensive regions of similarity of the low pi xylanase to xylanases from two different Bacillus species obtained from a publicly available data bank, and to a sequence within the partially cloned high pi xylanase gene (see FIG. 16).
  • the two cloned T ⁇ reesei xylanase genes will be fully characterized in order to ascertain the complete nucleotide sequence of the coding region, as well as the sequence of upstream and downstream regions.
  • the position of introns and the 5' and 3' ends of the transcribed region will be determined by sequence analysis of corresponding cDNA clones using methods known in the art.
  • a map of restriction endonuclease sites within the gene and its flanking regions will be generated.
  • T ⁇ reesei transformants will be obtained which overexpress either or both the high pi xylanase protein and the low pi xylanase protein. Additionally, T ⁇ reesei strains will be created which overexpress the low pi and/or high pi xylanase genes and which are unable to produce any or all of the cellulase components using the methods described in this application.
  • plasmids will be constructed in which all or part of the xylanase coding region will be deleted and replaced with a selectable marker such as the pyr4 gene.
  • the pyr4 gene could be inserted into the xylanase gene disrupting the coding region by the method shown in Example 16.
  • a linear substantially homologous DNA fragment containing the selectable marker flanked by sequences will be used to transform a T ⁇ reesei strain. In this way transformants will be created which are unable to produce a functional high pi or low pi xylanase or both.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Textile Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Prostheses (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP19910918551 1990-10-05 1991-10-04 Trichoderma reesei, die deletierte und/oder angereichertef zellulase und andere enzymgene enthält, und zellulasezusammensetzungen, die sich daraus ableiten Withdrawn EP0551394A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59391990A 1990-10-05 1990-10-05
US593919 1990-10-05

Publications (1)

Publication Number Publication Date
EP0551394A1 true EP0551394A1 (de) 1993-07-21

Family

ID=24376762

Family Applications (4)

Application Number Title Priority Date Filing Date
EP91918328A Revoked EP0551386B1 (de) 1990-10-05 1991-10-04 Methoden zur behandlung baumwolle-enthaltender fasern mit zellulase
EP91920379A Expired - Lifetime EP0553280B2 (de) 1990-10-05 1991-10-04 Methoden zur behandlung baumwolle-enthaltender fasern mit zellulase
EP19910918551 Withdrawn EP0551394A1 (de) 1990-10-05 1991-10-04 Trichoderma reesei, die deletierte und/oder angereichertef zellulase und andere enzymgene enthält, und zellulasezusammensetzungen, die sich daraus ableiten
EP20030025530 Withdrawn EP1416045A1 (de) 1990-10-05 1991-10-04 Aus Schimmelpilze Zellulase- enthaltende Zusammensetzung zur Behandlung Baumwolle-enthaltender Fasern

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP91918328A Revoked EP0551386B1 (de) 1990-10-05 1991-10-04 Methoden zur behandlung baumwolle-enthaltender fasern mit zellulase
EP91920379A Expired - Lifetime EP0553280B2 (de) 1990-10-05 1991-10-04 Methoden zur behandlung baumwolle-enthaltender fasern mit zellulase

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20030025530 Withdrawn EP1416045A1 (de) 1990-10-05 1991-10-04 Aus Schimmelpilze Zellulase- enthaltende Zusammensetzung zur Behandlung Baumwolle-enthaltender Fasern

Country Status (9)

Country Link
EP (4) EP0551386B1 (de)
JP (3) JPH06511379A (de)
AT (2) ATE257511T1 (de)
CA (3) CA2093421A1 (de)
DE (2) DE69133352T2 (de)
DK (2) DK0551386T3 (de)
ES (1) ES2170748T3 (de)
FI (3) FI120541B (de)
WO (1) WO1992006209A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988714A (zh) * 2017-12-29 2019-07-09 青岛蔚蓝生物集团有限公司 一种新型木霉及其应用

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837515A (en) * 1990-05-16 1998-11-17 Alko-Yhtiot Oy Enzyme preparations and methods for their production
US5997913A (en) * 1990-12-10 1999-12-07 Genencor International, Inc. Method enhancing flavor and aroma in foods by overexpression of β-glucosidase
EP2075338A3 (de) * 1990-12-10 2010-03-03 Genencor International, Inc. Verbesserte Verzuckerung von Zellulose durch Klonung und Amplifikation des ß-Glucosidase-Gens Trichoderma reesei
KR950701974A (ko) * 1992-05-29 1995-05-17 안티 쿠오카넨, 시스코 크누쓰-레에톨라 신규한 효소 제제 및 그의 제조방법(novel enzyme preparations and methods for their production)
US6251144B1 (en) 1992-06-12 2001-06-26 Genencor International, Inc. Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric and garments
US5665585A (en) * 1992-09-03 1997-09-09 Alko-Yhiot Oy Recombinant production of glucoamylase P in trichoderma
ES2316882T3 (es) * 1993-03-10 2009-04-16 Novozymes A/S Enzimas de aspergillus aculeatus con una actividad xilanasa.
DK81293D0 (da) * 1993-07-06 1993-07-06 Novo Nordisk As Enzym
US6268196B1 (en) 1993-12-17 2001-07-31 Genencor International, Inc. Method and compositions for treating cellulose containing fabrics using truncated cellulase enzyme compositions
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US7005128B1 (en) 1993-12-17 2006-02-28 Genencor International, Inc. Enzyme feed additive and animal feed including it
GB9416841D0 (en) * 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
EP0709452A1 (de) 1994-10-27 1996-05-01 The Procter & Gamble Company Xylanasenhaltige Reinigungsmittel
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US6723549B2 (en) 1995-10-17 2004-04-20 Ab Enzymes Oy Cellulases, the genes encoding them and uses thereof
US6184019B1 (en) 1995-10-17 2001-02-06 Röhm Enzyme Finland OY Cellulases, the genes encoding them and uses thereof
FI964692A0 (fi) * 1996-11-25 1996-11-25 Primalco Ltd Foerbaettrad cellulassammansaettning foer bioefterbehandling av textilmaterial som innehaoller cellulosa
FI964691A0 (fi) * 1996-11-25 1996-11-25 Primalco Ltd Foerbaettrad cellulassammasaettning foer behandling av textilmaterial som innehaoller cellulosa
CA2274112A1 (en) 1996-12-06 1998-06-11 Diversa Corporation Glycosidase enzymes
JP4261044B2 (ja) 1997-07-11 2009-04-30 ジェネンコア インターナショナル インコーポレーテッド トリコデルマリーセイスウォレニンタンパク質およびコード化dna配列
US6407046B1 (en) 1998-09-03 2002-06-18 Genencor International, Inc. Mutant EGIII cellulase, DNA encoding such EGIII compositions and methods for obtaining same
US7977051B2 (en) 1999-04-10 2011-07-12 Danisco Us Inc. EGIII-like enzymes, DNA encoding such enzymes and methods for producing such enzymes
US6623949B1 (en) 2000-08-04 2003-09-23 Genencor International, Inc. Variant EGIII-like cellulase compositions
US6635465B1 (en) 2000-08-04 2003-10-21 Genencor International, Inc. Mutant EGIII cellulase, DNA encoding such EGIII compositions and methods for obtaining same
EP2305801B1 (de) 2002-08-16 2017-07-05 Danisco US Inc. Neuartige abweichende Hypocrea-jecorina-CBH1-Cellulasen
JP4744879B2 (ja) 2002-11-07 2011-08-10 ジェネンコー・インターナショナル・インク BGL6β−グルコシダーゼ及びそれをエンコードする核酸
US8278079B2 (en) 2002-11-07 2012-10-02 Danisco Us Inc. BGL6 β-glucosidase and nucleic acids encoding the same
EP1606392A4 (de) 2003-03-21 2007-10-17 Genencor Int Neue cbh1-homologe und cbh1-cellulasevarianten
WO2005001065A2 (en) 2003-04-01 2005-01-06 Genencor International, Inc. Variant humicola grisea cbh1.1
DK1862626T3 (da) 2003-05-29 2011-12-12 Genencor Int Nye Trichoderma-gener
CN102174490B (zh) 2003-11-21 2016-09-28 丹尼斯科美国公司 颗粒淀粉水解酶在木霉菌中的表达和从颗粒淀粉底物产生葡萄糖的方法
ATE489457T1 (de) 2004-01-16 2010-12-15 Novozymes Inc Verfahren zum abbau von lignocellulosematerialien
DK2314605T3 (da) 2004-01-30 2014-06-16 Novozymes Inc Polypeptider med cellulolytisk forøgende aktivitet og polynukleotider, der koder for disse
EP2354222A1 (de) 2004-03-25 2011-08-10 Genencor International, Inc. Cellulase-Fusionsprotein und heterologes Cellulase-Fusionskonstrukt, das dieses Fusionsprotein kodiert
US8097445B2 (en) 2004-03-25 2012-01-17 Danisco Us Inc. Exo-endo cellulase fusion protein
US7413887B2 (en) 2004-05-27 2008-08-19 Genecor International, Inc. Trichoderma reesei glucoamylase and homologs thereof
WO2005118795A2 (en) 2004-05-27 2005-12-15 Genencor International, Inc. Aspergillus kawachi acid-stable alpha amylase and applications in granular starch hydrolysis
AU2004320371B2 (en) 2004-05-27 2011-09-22 Genencor International, Inc. Heterologous expression of an aspergillus kawachi acid-stable alpha amylase and applications in granular starch hydrolysis
US7332319B2 (en) 2004-05-27 2008-02-19 Genencor International, Inc. Heterologous alpha amylase expression in Aspergillus
CN101094917B (zh) 2004-12-30 2012-04-25 金克克国际有限公司 新型变体红褐肉座菌cbh2纤维素酶
US8034600B2 (en) 2005-02-18 2011-10-11 Danisco Us Inc. Polypeptides having alpha-amylase and granular starch hydrolyzing activity
NZ589570A (en) 2005-09-30 2012-06-29 Novozymes Inc Methods for enhancing the degradation or conversion of cellulosic material
BRPI0714870A2 (pt) 2006-07-21 2013-05-28 Novozymes Inc mÉtodo para produzir um polipeptÍdeo secretado tendo atividade biolàgica, proteÍna de fusço isolada, polinucleotÍdeo isolado, construÇço de proteÍna de fusço, vetor de expressço, cÉlula hospedeira féngica, mÉtodos para degradar ou conventer um material celulàsico e para produzir uma substÂncia
BRPI0719181A2 (pt) 2006-10-10 2014-08-05 Danisco Us Inc Genencor Div Variantes de glucoamilase com propriedades alteradas
WO2009048488A1 (en) 2007-10-09 2009-04-16 Danisco Us, Inc., Genencor Division Glucoamylase variants with altered properties
EP2121911A2 (de) 2007-01-18 2009-11-25 Danisco US, INC., Genencor Division Modifizierte endoglucanase ii und verwendungsverfahren
ES2376059T3 (es) 2007-03-14 2012-03-08 Danisco Us Inc. La a-amilasa de trichoderma reesei es una enzima maltogénica.
US8592194B2 (en) 2007-10-09 2013-11-26 Danisco Us Inc. Glucoamylase variants with altered properties
DK2201108T3 (en) 2007-10-18 2015-01-05 Danisco Us Inc Compounds for enzyme fermentation
CN101868537B (zh) 2007-11-20 2013-11-06 丹尼斯科美国公司 具有改变性质的葡糖淀粉酶变体
EP2268806B1 (de) 2008-02-11 2013-04-10 Danisco US Inc. Enzym mit mikrobieller Lyseaktivität aus Trichoderma reesei
US8354256B2 (en) 2008-03-11 2013-01-15 Danisco Us Inc. Glucoamylase and Buttiauxiella phytase during saccharification
EP2628795A1 (de) 2008-06-06 2013-08-21 Danisco US Inc. Zusammensetzungen und Verfahren mit Cellulasevarianten mit verminderter Affinität gegenüber cellulosefreien Materialien
CA2764094A1 (en) 2009-06-03 2010-12-09 Danisco Us Inc. Cellulase variants with improved expression, activity and/or stability, and use thereof
WO2011022465A1 (en) 2009-08-19 2011-02-24 Danisco Us Inc. Combinatorial variants of glucoamylase with improved specific activity and/or thermostability
MX2012002032A (es) 2009-08-19 2012-03-26 Danisco Variantes de glucoamilasa.
DK2599863T3 (da) 2009-11-20 2017-11-06 Danisco Us Inc Beta-glucosidasevarianter med forbedrede egenskaber
CN102939382B (zh) 2010-06-03 2017-02-15 丹尼斯科美国公司 丝状真菌宿主菌株和dna构建体以及它们的使用方法
AR082578A1 (es) 2010-08-06 2012-12-19 Danisco Us Inc SACARIFICACION Y FERMENTACION A pH NEUTRO
WO2012019169A1 (en) 2010-08-06 2012-02-09 Danisco Us Inc. Production of isoprene under neutral ph conditions
JP2013535983A (ja) 2010-08-24 2013-09-19 ダニスコ・ユーエス・インク 低温コメタンパク質濃縮物を含有する食品
GB201102857D0 (en) * 2011-02-18 2011-04-06 Danisco Feed additive composition
EP2702163A1 (de) 2011-04-29 2014-03-05 Danisco US Inc. Einzel-ph-verfahren zur verflüssigung von stärke und zur verzuckerung hochdichter glucosesirups
BR112014002745A8 (pt) 2011-08-05 2017-06-20 Danisco Us Inc produção de isoprenoides sob condições de ph neutro
CN103890180A (zh) 2011-08-24 2014-06-25 诺维信股份有限公司 在丝状真菌宿主细胞中产生多种重组多肽的方法
EP2758514B2 (de) 2011-09-22 2020-03-18 Danisco US Inc. Endogene dnase-wirkung zur reduzierung eines dna-inhalts
MX2015002099A (es) 2012-08-22 2015-05-11 Dupont Nutrition Biosci Aps Variantes que tienen actividad glucoamilasa.
MX2015007236A (es) 2012-12-12 2015-10-29 Danisco Us Inc Variantes de celobiohidrolasas.
US20150315560A1 (en) 2012-12-12 2015-11-05 Danisco Us Inc. Variants of cellobiohydrolases
US20160272959A1 (en) 2012-12-12 2016-09-22 Danisco Us Inc. Variants of cellobiohydrolases
CN104870644A (zh) 2012-12-12 2015-08-26 丹尼斯科美国公司 纤维二糖水解酶的变体
MX2015007233A (es) 2012-12-12 2015-10-29 Danisco Us Inc Variantes de celobiohidrolasas.
JP2014150745A (ja) * 2013-02-06 2014-08-25 Nagaoka Univ Of Technology トリコデルマ属に属する微生物の変異株および該変異株の使用
MX2016001315A (es) 2013-07-29 2016-04-07 Danisco Us Inc Variantes de enzimas.
ES2749211T3 (es) 2013-12-04 2020-03-19 Danisco Us Inc Variantes de glucoamilasa
EP3099792B1 (de) 2014-01-31 2018-10-17 Danisco US Inc. Verfahren zur verbesserung von nebenprodukten fermentationsverfahren mit xylanase
EP3234166A1 (de) 2014-12-19 2017-10-25 Danisco US Inc. Glucoamylasemischungen
DK3298138T3 (da) 2015-05-22 2022-10-31 Dupont Nutrition Biosci Aps Acetolactatdecarboxylase
US20180142228A1 (en) 2015-05-22 2018-05-24 Dupont Nutrition Biosciences Aps Aldc production methods
EP3192866A1 (de) 2016-01-15 2017-07-19 CIC nanoGUNE - Asociación Centro de Investigación Cooperativa en Nanociencias Endocellulasen und verwendungen davon
WO2018050649A1 (en) 2016-09-16 2018-03-22 Dupont Nutrition Biosciences Aps Acetolactate decarboxylase variants having improved specific activity
KR102593668B1 (ko) 2016-10-04 2023-10-24 다니스코 유에스 인크. 유도 기질 부재 하의 사상 진균 세포에서의 단백질 생산
EP3502126A1 (de) 2017-12-19 2019-06-26 CIC nanoGUNE - Asociación Centro de Investigación Cooperativa en Nanociencias Anzestrale cellulasen und verwendungen davon
KR20210038591A (ko) 2018-07-30 2021-04-07 다니스코 유에스 인크. 향상된 단백질 생산성 표현형을 포함하는 돌연변이체 및 유전자 변형된 사상성 진균 균주 및 이의 방법
US11339516B2 (en) * 2018-09-27 2022-05-24 Sanko Tekstil Isletmeleri San. Ve Tic. A.S. Dyed fabric finishing process
MX2021005825A (es) 2018-11-20 2021-08-05 Dupont Nutrition Biosci Aps Polipéptidos del clado de fitasa con alta temperatura de desnaturalización (tm) robustos modificados por ingeniería genética y fragmentos de los mismos.
MX2022000077A (es) 2019-07-01 2022-05-20 Cotton Inc Tela de desecho de textil de algodón usada como biomasa para producción de azúcar.
WO2021102238A1 (en) 2019-11-20 2021-05-27 Dupont Nutrition Biosciences Aps Thermostable phytase variants
EP3872172A1 (de) 2020-02-28 2021-09-01 CIC nanoGUNE - Asociación Centro de Investigación Cooperativa en Nanociencias Leitfähige celluloseverbundmaterialien und verwendungen davon
EP3872173A1 (de) 2020-02-28 2021-09-01 CIC nanoGUNE - Asociación Centro de Investigación Cooperativa en Nanociencias Verfahren zur herstellung von kristalliner nanocellulose
WO2021173974A1 (en) 2020-02-28 2021-09-02 Dupont Nutrition Biosciences Aps Feed compositions
CN115427434A (zh) 2020-04-22 2022-12-02 丹尼斯科美国公司 用于增强丝状真菌细胞中的蛋白质产生的组合物和方法
WO2024124013A1 (en) 2022-12-09 2024-06-13 International N&H Denmark Aps Feed formulations comprising a phytase for dairy ruminant animals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI841500A0 (fi) * 1984-04-13 1984-04-13 Valtion Teknillinen Foerfarande foer uppbygnande av cellulolytiska jaeststammar.
EP0406314B1 (de) * 1988-03-24 1993-12-01 Novo Nordisk A/S Cellulosezubereitung
DE69024499T2 (de) * 1989-10-19 1996-07-11 Genencor Int Abbaubeständige reinigungszusammensetzungen
CA2107208A1 (en) * 1991-03-29 1992-09-30 Kathleen A. Clarkson Methods for treating cotton-containing fabrics with cellulase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9206209A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988714A (zh) * 2017-12-29 2019-07-09 青岛蔚蓝生物集团有限公司 一种新型木霉及其应用

Also Published As

Publication number Publication date
EP0553280A4 (en) 1993-12-01
CA2093428C (en) 1996-06-11
ATE211773T1 (de) 2002-01-15
EP1416045A1 (de) 2004-05-06
CA2093424C (en) 2000-05-02
DK0553280T3 (da) 2002-04-29
EP0551386B1 (de) 2004-01-07
EP0553280B1 (de) 2002-01-09
FI931495A (fi) 1993-05-27
ES2170748T3 (es) 2002-08-16
WO1992006209A1 (en) 1992-04-16
FI931491A (fi) 1993-05-25
FI931491A0 (fi) 1993-04-01
DE69132894D1 (de) 2002-02-14
JPH06502226A (ja) 1994-03-10
FI931495A0 (fi) 1993-04-01
EP0551386A4 (en) 1993-12-01
DK0551386T3 (da) 2004-05-10
FI931492A0 (fi) 1993-04-01
CA2093421A1 (en) 1992-04-06
DE69132894T3 (de) 2011-03-03
CA2093424A1 (en) 1992-04-06
DE69133352D1 (de) 2004-02-12
CA2093428A1 (en) 1992-04-06
EP0553280B2 (de) 2010-08-11
DE69132894T2 (de) 2002-08-14
DK0553280T4 (da) 2010-11-15
EP0553280A1 (de) 1993-08-04
ATE257511T1 (de) 2004-01-15
JPH06502223A (ja) 1994-03-10
FI931492A (fi) 1993-04-01
JPH06511379A (ja) 1994-12-22
DE69133352T2 (de) 2004-11-04
EP0551386A1 (de) 1993-07-21
FI120541B (fi) 2009-11-30

Similar Documents

Publication Publication Date Title
WO1992006209A1 (en) Trichoderma reesei containing deleted and/or enriched cellulase and other enzyme genes and cellulase compositions derived therefrom
EP0586375B1 (de) Detergentien-verbindungen, die substantiell reine eg iii-zellulase enthalten
EP0877077B1 (de) Cellulasezusammensetzungen mit einem Defizit an Komponenten des Typs-CBH I enthaltende Reinigungsmittelzusammensetzungen
EP0635057B1 (de) Verfahren zur herstellung von eg iii zellulase, xylanase oder eine mischung davon mit polyäthylenglycol
CA2093425A1 (en) Detergent compositions containing cellulase compositions enriched in acidic endoglucanase type components
WO1992006183A1 (en) Methods for treating cotton-containing fabrics with cellulase
JPH06506829A (ja) セルラーゼによる綿含有織物の処理方法
US5668009A (en) Methods for treating cotton-containing fabrics with CBH I enriched cellulase
EP0633938B1 (de) Methoden zur herstellung praktisch reiner eg iii zellulase mittels alkohol
JPH06506359A (ja) セルラーゼによる綿含有織物の処理方法
US5472864A (en) Method of preparing solution enriched in EG III using low molecular weight alcohol, organic salt and inorganic salt
JP3522272B6 (ja) ポリエチレングリコールを用いた実質的に純粋なeg ▲iii▼セルラーゼの製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WARD, MICHAEL

Inventor name: SHOEMAKER, SHARON, P.

Inventor name: WEISS, GEOFFREY, L.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960405